Home › Research › Lewy body dementia
Plasma p‐tau217 and Aβ42/40 as markers of Aβ pathology in the Lewy body continuum
Kyung Ah Woo, Eun Jin Yoon, Ryul Kim, Heejung Kim, Seo-Yeon Kim, Bora Jin, Seungmin Lee, Yu Kyeong Kim et al.. Alzheimer s & Dementia, 2025-10-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
Higher plasma p-tau217, lower Aβ42/40, and their interaction were associated with greater Aβ-PET uptake. Individuals with higher-than-median p-tau217 and lower-than-median Aβ42/40 showed the highest Aβ burden. Both biomarkers predicted Aβ-PET positivity, but only p-tau217 correlated with cognition. Among 44 iRBD participants followed prospectively, elevated baseline p-tau217 predicted phenoconversion to overt Lewy body disease. Plasma p-tau217 and Aβ42/40 may serve as accessible biomarkers of cerebral Aβ pathology and help identify individuals across the Lewy body continuum who could benefit from Aβ-targeted therapy. HIGHLIGHTS: Plasma phosphorylated tau-217 (p-tau217) and amyloid beta (Aβ)42/40 predict cerebral Aβ burden in the Lewy body continuum. Both biomarkers individually show high accuracy for identifying Aβ positron emission tomography positivity. Plasma p-tau217, but not Aβ42/40, is associated with cognitive performance. Elevated plasma p-tau217 predicts future phenoconversion in isolated rapid eye movement sleep behavior disorder.
What this study adds
Evidence grade: Low
This study found that plasma p-tau217 and Aβ42/40 may serve as accessible biomarkers of cerebral Aβ pathology and help identify individuals across the Lewy body continuum who could benefit from Aβ-targeted therapy. It is about identifying who might benefit from existing therapy, not about a new treatment, cure or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Woo, K. A., Yoon, E. J., Kim, R., Kim, H., Kim, S.-Y., Jin, B., et al. (2025). Plasma p‐tau217 and Aβ42/40 as markers of Aβ pathology in the Lewy body continuum. Alzheimer s & Dementia. https://doi.org/10.1002/alz.70788
Vancouver
Woo KA, Yoon EJ, Kim R, Kim H, Kim S.-Y, Jin B, et al. Plasma p‐tau217 and Aβ42/40 as markers of Aβ pathology in the Lewy body continuum. Alzheimer s & Dementia. 2025. doi:10.1002/alz.70788. PMID: 41075284.
BibTeX
@article{woo2025-41075284,
author = {Woo, Kyung Ah and Yoon, Eun Jin and Kim, Ryul and Kim, Heejung and Kim, Seo-Yeon and Jin, Bora and Lee, Seungmin and Kim, Yu Kyeong and others},
title = {{Plasma p‐tau217 and Aβ42/40 as markers of Aβ pathology in the Lewy body continuum}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz.70788},
pmid = {41075284},
url = {https://doi.org/10.1002/alz.70788}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Higher plasma p-tau217, lower Aβ42/40, and their interaction were associated with greater Aβ-PET uptake.
- Individuals with higher-than-median p-tau217 and lower-than-median Aβ42/40 showed the highest Aβ burden.
- Both biomarkers predicted Aβ-PET positivity, but only p-tau217 correlated with cognition.
- Among 44 iRBD participants followed prospectively, elevated baseline p-tau217 predicted phenoconversion to overt Lewy body disease.
- Plasma p-tau217 and Aβ42/40 may serve as accessible biomarkers of cerebral Aβ pathology and help identify individuals across the Lewy body continuum who could benefit from Aβ-targeted therapy.
Why it matters
This study found that plasma p-tau217 and Aβ42/40 may serve as accessible biomarkers of cerebral Aβ pathology and help identify individuals across the Lewy body continuum who could benefit from Aβ-targeted therapy. It is about identifying who might benefit from existing therapy, not about a new treatment, cure or prevention.
Study details
- Evidence strengthLow
How this study scored 43/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 6 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 3.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Jee‐Young Lee: h-index 43 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 10 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41075284) |
| Free to read | 2 / 2 | Free to read |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.
Related studies in Lewy body dementia from nearby years
Also tagged “phosphorylated”
733 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 733 tagged studies.